– USA, MA – Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, today announced the appointment of Dr. Greg Moore (M.D., Ph.D.) to its Board of Directors, bringing extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies.
“Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation. From his work at Google, Microsoft, and Geisinger, to his clinical experience, Greg has been at the forefront of leveraging data and AI to transform medicine. We welcome Greg’s expertise and guidance as Cellarity advances its platform and uncovers novel biology and treatments across a vast array of disease areas,” said Board Chairman, Steve Berenson.
About Dr. Gregory J. Moore
At Microsoft, Dr. Moore was the lead executive responsible for the integration of the recent acquisition of Nuance ($19.7 billion) and the creation of a new healthcare and life sciences product and engineering division for Microsoft. He is a pioneer in the technology industry, leading the development of cloud-based AI and healthcare data interoperability platforms at two big tech companies to deploy commercial-grade enterprise software empowering the healthcare and life sciences industry to provide better care for patients, and to accelerate biomedical research and the development of novel therapeutics. Before Microsoft, he served as Vice President at Google and was the founder of Google Cloud Health and Life Sciences. Dr. Moore is board certified in Diagnostic Radiology, Neuroradiology, and Clinical Informatics. Before his executive leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, where he was also Director of the Institute of Advanced Application, Interim Chair of System Radiology, and a practicing neuroradiologist. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. He currently serves as an independent director on the boards of DaVita (NYSE: DVA) and Olink Holding AB (NASDAQ: OLK).
Dr. Moore said, “Cellarity’s single-cell AI platform is an entirely new approach to drug creation. By embracing the complexity of disease biology and providing novel insights into cellular dysfunction, instead of focusing on a single target, the Cellarity platform can generate novel medicines that otherwise wouldn’t have been discovered. I look forward to helping Cellarity lead a new era of drug discovery.”
About Cellarity
Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to develop medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single-cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs in several areas, including metabolic disease, hematology, and immuno-oncology.
Source: https://cellarity.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.